Published in Cell Growth Differ on October 01, 1991
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70
MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene (2011) 1.59
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A (2004) 1.57
MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun (2006) 1.42
Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther (2009) 0.99
Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis (1997) 0.96
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Dev Biol (2011) 0.94
The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med (2009) 0.89
Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells. J Biomed Sci (2011) 0.87
MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation. Semin Cancer Biol (2011) 0.84
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget (2015) 0.81
Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin. Oncotarget (2015) 0.79
KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma. BMC Cancer (2016) 0.78
Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer (1996) 0.78
Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis. PLoS One (2015) 0.76
Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation. Mol Oncol (2015) 0.76
MYCN, neuroblastoma and focal adhesion kinase (FAK). Front Biosci (Elite Ed) (2011) 0.76
Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance. Genome Med (2017) 0.75
Cell Proliferation in Neuroblastoma. Cancers (Basel) (2016) 0.75
Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation. Oncotarget (2017) 0.75
CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells. Front Mol Neurosci (2017) 0.75
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J (1995) 3.48
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
ISWI is an ATP-dependent nucleosome remodeling factor. Mol Cell (1999) 2.68
Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34
The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J (1992) 2.18
MAC1, a nuclear regulatory protein related to Cu-dependent transcription factors is involved in Cu/Fe utilization and stress resistance in yeast. EMBO J (1993) 2.13
Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol (2000) 2.06
Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem (1998) 1.86
Acf1, the largest subunit of CHRAC, regulates ISWI-induced nucleosome remodelling. EMBO J (2001) 1.81
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol (1998) 1.80
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80
Replacement of 5-methylcytosine by cytosine: a possible mechanism for transient DNA demethylation during differentiation. Proc Natl Acad Sci U S A (1986) 1.79
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77
Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71
Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest (1997) 1.70
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br (2002) 1.58
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56
Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J (1998) 1.50
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol (2003) 1.46
Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. Am J Clin Nutr (1994) 1.46
Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol (2000) 1.45
Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology (2003) 1.45
[ General postural rehabilitation in musculoskeletal diseases: scientific evidence and clinical indications]. Reumatismo (2007) 1.44
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol (2009) 1.44
Establishment and characterization of a human neuroblastoma cell line. Int J Cancer (1989) 1.43
Sudden infant death and multiple acyl-CoA dehydrogenation disorders. Eur J Pediatr (1995) 1.43
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
Absolute alcohol in esophageal vein sclerosis. Gastrointest Endosc (1988) 1.40
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.39
Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia. Hum Gene Ther (1999) 1.39
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39
Severe hepatorenal failure in a child receiving carbamazepine and erythromycin. Eur J Pediatr (1992) 1.38
Gene expression profiling in MDS and AML: potential and future avenues. Leukemia (2011) 1.38
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest (1999) 1.37
Hmg4, a new member of the Hmg1/2 gene family. Genomics (1998) 1.37
Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem (1993) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Group B streptococci persist inside macrophages. Immunology (1998) 1.36
Structural and functional analysis of a growth-regulated gene, the human calcyclin. J Biol Chem (1987) 1.36
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer (2001) 1.34
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33
Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol (1993) 1.32
Template-imprinted nanostructured surfaces for protein recognition. Nature (1999) 1.32
Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer (2001) 1.31
Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem (1999) 1.30
Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 1.30
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Different brain correlates for watching real and virtual hand actions. Neuroimage (2001) 1.28
Molecular cloning of a cDNA for a human ADP/ATP carrier which is growth-regulated. J Biol Chem (1987) 1.27
Differential response of embryonic and fetal myoblasts to TGF beta: a possible regulatory mechanism of skeletal muscle histogenesis. Development (1994) 1.25
Shoulder arthroplasty for the treatment of the sequelae of fractures of the proximal humerus. J Shoulder Elbow Surg (2001) 1.24
Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene (2000) 1.24
Activation of c-myb expression by phytohemagglutinin stimulation in normal human T lymphocytes. Mol Cell Biol (1985) 1.22
A stimulated S6 kinase from rat liver: identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J (1989) 1.22
Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. J Med Virol (1995) 1.22
Cystine accumulation and clearance by normal and cystinotic leukocytes exposed to cystine dimethyl ester. Proc Natl Acad Sci U S A (1982) 1.21
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem (2000) 1.21
Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol (1993) 1.19
Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. Proc Natl Acad Sci U S A (1996) 1.19
Two histone fold proteins, CHRAC-14 and CHRAC-16, are developmentally regulated subunits of chromatin accessibility complex (CHRAC). EMBO J (2000) 1.18
Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction. Blood (1991) 1.17
High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol (2002) 1.17
Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer (1993) 1.16
Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem (2001) 1.16
Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand (1998) 1.16
Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 1.15
The dynamics of myogenin site-specific demethylation is strongly correlated with its expression and with muscle differentiation. J Biol Chem (2000) 1.15
Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 1.15
Unmasking a growth factor/oncogene-activated S6 phosphorylation cascade. Cell Signal (1989) 1.14
G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent. Leukemia (2006) 1.13
Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther (2001) 1.13
Inhibition of Aurora A in response to DNA damage. Oncogene (2006) 1.13
The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase 4. J Cell Sci (2001) 1.13
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Regulation of B-Myb activity by cyclin D1. Oncogene (2000) 1.12
Chondrosarcoma of the temporomandibular joint: a case report and review of the literature. J Oral Maxillofac Surg (1997) 1.12
West syndrome associated with 14q12 duplications harboring FOXG1. Neurology (2011) 1.12
Study of immune complexes in bronchoalveolar lavage fluids. Respiration (1988) 1.11
HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia. Science (1987) 1.10
IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci (1995) 1.08
T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy (2000) 1.08
Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res (1999) 1.08
Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer (2004) 1.08
Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J Exp Med (1996) 1.08